CIK 0001287098 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MAXCYTE, INC.
Sign in to watch- Ticker
- MXCT
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522210438
- Phone
- 301-517-5556
- Business address
- 9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850
- Former names
- MAXCYTE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 42 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-18 | BALTHROP PATRICK J Director | Grant or award · Stock Option (right to buy) | +50,790 | 50,790 | ||
| 2025-06-18 | Al-Wakeel Yasir B. Director | Grant or award | +29,210 | 50,577 | ||
| 2025-06-18 | Al-Wakeel Yasir B. Director | Grant or award · Stock Option (right to buy) | +50,790 | 50,790 | ||
| 2025-03-18 | Soleymannezhad Ali Chief Commercial Officer | Sale | −1,211 | $3.18 | $4K | 59,439 |
| 2025-03-18 | Sandoval David I. GENERAL COUNSEL | Sale | −353 | $3.18 | $1K | 64,219 |
| 2025-03-18 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Sale | −6,939 | $3.18 | $22K | 111,811 |
| 2025-03-14 | Soleymannezhad Ali Chief Commercial Officer | Grant or award | +34,625 | 60,650 | ||
| 2025-03-14 | Soleymannezhad Ali Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +138,500 | 138,500 | ||
| 2025-03-14 | Sandoval David I. GENERAL COUNSEL | Grant or award | +23,125 | 64,572 | ||
| 2025-03-14 | Sandoval David I. GENERAL COUNSEL | Grant or award · Employee Stock Option (right to buy) | +92,500 | 92,500 | ||
| 2025-03-14 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Grant or award | +37,500 | 118,750 | ||
| 2025-03-14 | Swirsky Douglas J CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-03-14 | Masoud Maher President and CEO | Grant or award · Employee Stock Option (right to buy) | +347,500 | 347,500 | ||
| 2025-01-27 | Johnston John Joseph Director | Option exercise 10b5-1 | +3,000 | $2.93 | $9K | 144,950 |
| 2025-01-27 | Johnston John Joseph Director | Sale 10b5-1 | −3,000 | $4.65 | $14K | 141,950 |
| 2025-01-27 | Johnston John Joseph Director | Option exercise · Stock Option (right to buy) 10b5-1 | −3,000 | 17,417 | ||
| 2025-01-13 | Sandoval David I. GENERAL COUNSEL | Sale | −4,466 | $4.54 | $20K | 41,447 |
| 2024-12-26 | Johnston John Joseph Director | Option exercise 10b5-1 | +3,000 | $2.93 | $9K | 144,950 |
| 2024-12-26 | Johnston John Joseph Director | Sale 10b5-1 | −3,000 | $4.01 | $12K | 141,950 |
| 2024-12-26 | Johnston John Joseph Director | Option exercise · Stock Option (right to buy) 10b5-1 | −3,000 | 20,417 |
Page 3 of 15 · 282 trades